(a) Content of notice. For each sales year, the IRS will make a preliminary calculation of the fee for each covered entity as described in Sec. 51.5. The IRS will notify each covered entity of its preliminary fee calculation for that sales year. The notification to a covered entity of its preliminary fee calculation will include--
(1) The covered entity's allocated fee;
(2) The covered entity's branded prescription drug sales, by NDC, by Program;
(3) The covered entity's branded prescription drug sales taken into account after application of Sec. 51.5(a)(4);
(4) The aggregate branded prescription drug sales taken into account for all covered entities;
(5) The covered entity's adjustment amount calculated as described in Sec. 51.5(e); and
(6) A reference to the fee dispute resolution procedures set forth in guidance published in the Internal Revenue Bulletin.
(b) Time of notice. The IRS will send each covered entity notice of its preliminary fee calculation by the date prescribed in guidance published in the Internal Revenue Bulletin. [T.D. 9684, 79 FR 43644, July 28, 2014]